Ziprasidone

Ziprasidone

  • Risk of orthostatic hypotension and sedation
  • Greatest QTc prolongation
    • Caution in QTc prolongation, recent myocardial infarction, or uncompensated heart failure

Dose:

10–20 mg IM (onset 30–45 minutes)
Not to exceed 40 mg in 24-hour period

References

Rais AR, Williams K, Rais T, Singh T, Tamburrino M. Use of intramuscular ziprasidone for the control of acute psychosis or agitation in an inpatient geriatric population: an open-label study. Psychiatry (Edgmont). 2010;7(1):17–24

Kohen I, Preval H, Southard R, Francis A. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service. Am J Geriatr Pharmacother. 2005;3(4):240–245